Enhanced Release of Glucose Into the Intraluminal Space of the Intestine Associated With Metformin Treatment as Revealed by [18F]Fluorodeoxyglucose PET-MRI
- 3 June 2020
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 43 (8), 1796-1802
- https://doi.org/10.2337/dc20-0093
Abstract
OBJECTIVE Positron emission tomography (PET)–computed tomography has revealed that metformin promotes the intestinal accumulation of [18F]fluorodeoxyglucose (FDG), a nonmetabolizable glucose derivative. It has remained unknown, however, whether this accumulation occurs in the wall or intraluminal space of the intestine. We here addressed this question with the use of [18F]FDG PET-MRI, a recently developed imaging method with increased accuracy of registration and high soft-tissue contrast. RESEARCH DESIGN AND METHODS Among 244 individuals with type 2 diabetes who underwent PET-MRI, we extracted 24 pairs of subjects matched for age, BMI, and HbA1c level who were receiving treatment with metformin (metformin group) or were not (control group). We evaluated accumulation of [18F]FDG in different portions of the intestine with both a visual scale and measurement of maximum standardized uptake value (SUVmax), and such accumulation within the intestinal wall or lumen was discriminated on the basis of SUVmax. RESULTS SUVmax of the jejunum, ileum, and right or left hemicolon was greater in the metformin group than in the control group. [18F]FDG accumulation in the ileum and right or left hemicolon, as assessed with the visual scale, was also greater in the metformin group. SUVmax for the intraluminal space of the ileum and right or left hemicolon, but not that for the intestinal wall, was greater in the metformin group than in the control group. CONCLUSIONS Metformin treatment was associated with increased accumulation of [18F]FDG in the intraluminal space of the intestine, suggesting that this drug promotes the transport of glucose from the circulation into stool.This publication has 40 references indexed in Scilit:
- Metformin Temporal and Localized Effects on Gut Glucose Metabolism Assessed Using 18F-FDG PET in MiceJournal of Nuclear Medicine, 2013
- GLUT2 Accumulation in Enterocyte Apical and Intracellular MembranesDiabetes, 2011
- High Incidence of Metabolically Active Brown Adipose Tissue in Healthy Adult HumansDiabetes, 2009
- Identification and Importance of Brown Adipose Tissue in Adult HumansThe New England Journal of Medicine, 2009
- Advances in radiological imaging of gastrointestinal tumorsCritical Reviews in Oncology/Hematology, 2009
- State-of-the-Art Computed Tomographic and Magnetic Resonance Imaging of the Gastrointestinal SystemGastrointestinal Endoscopy Clinics of North America, 2005
- 5-Aminoimidazole-4-carboxamide riboside (AICAR) enhances GLUT2-dependent jejunal glucose transport: a possible role for AMPKBiochemical Journal, 2005
- Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucoseEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Importance of the intestine as a site of metformin‐stimulated glucose utilizationBritish Journal of Pharmacology, 1994
- Sites of metformin-stimulated glucose metabolismBiochemical Pharmacology, 1990